New Risk • Jun 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (144% accrual ratio). Market cap is less than US$10m (₹149.2m market cap, or US$1.57m). Minor Risks Latest financial reports are more than 6 months old (reported September 2025 fiscal period end). Share price has been volatile over the past 3 months (9.5% average weekly change). Annuncio • Feb 03
Supha Pharmachem Limited to Report Q3, 2026 Results on Feb 14, 2026 Supha Pharmachem Limited announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 14, 2026 Valuation Update With 7 Day Price Move • Nov 26
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹1.15, the stock trades at a trailing P/E ratio of 3.8x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 33% over the past three years. Reported Earnings • Nov 16
Second quarter 2026 earnings released: EPS: ₹0.10 (vs ₹0.04 in 2Q 2025) Second quarter 2026 results: EPS: ₹0.10 (up from ₹0.04 in 2Q 2025). Revenue: ₹1.14b (up 356% from 2Q 2025). Net income: ₹86.2m (up 386% from 2Q 2025). Profit margin: 7.5% (up from 7.1% in 2Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. New Risk • Nov 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.07x net interest cover). Market cap is less than US$10m (₹608.8m market cap, or US$6.86m). Minor Risk Share price has been volatile over the past 3 months (7.0% average weekly change). Annuncio • Nov 08
Remedium Lifecare Limited to Report Q2, 2026 Results on Nov 14, 2025 Remedium Lifecare Limited announced that they will report Q2, 2026 results on Nov 14, 2025 Annuncio • Oct 31
Remedium Lifecare Limited Reconstitutes Its Committees The Board of Directors of Remedium Lifecare Limited at its meeting held on 31 October 2025 has inter- alia considered, approved and taken on record: The Board has reconstituted its committee(s) on account of a change in board members. As per Regulation 18 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Audit Committee has been reconstituted as follows: Mr. Vijay Pal Singh Gulya (w.e.f. 31st October 2025), Independent Director as Chairman; Mrs. Shamim Adil Michal (appointed on 22.01.25), Independent Director and Mr. Rambhajan Vishwakarma (w.e.f. 31st October, 2025), Non-Executive /Non-Independent Director as Members. As per Regulation 19 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Nomination and Remuneration Committee has been reconstituted as follows: Mrs. Shamim Adil Michal (appointed on 22.01.25), Independent Director as Chairperson; Mr. Vijay Pal Singh Gulya (w.e.f. 31st October 2025), Independent Director and Mr. Rambhajan Vishwakarma (w.e.f. 31st October, 2025), Non-Executive /Non-Independent Director as Members. As per Regulation 20 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Stakeholders' Relationship Committee has been reconstituted as follows: Mr. Rambhajan Vishwakarma (w.e.f. 31st October 2025), Non-Executive /Non-Independent Director as Chairman; Mrs. Shamim Adil Michal (appointed on 22.01.25), Independent Director and Mr. Vijay Pal Singh Gulya (w.e.f. 31st October, 2025), Independent Director as Members. As per Regulation 21 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Risk Management Committee has been reconstituted as follows: Mrs. Shamim Adil Michal (appointed on 22.01.25), Independent Director as Chairperson; Mr. Adarsh Munjal, Executive Director and Mr. Vijay Pal Singh Gulya (w.e.f. 31st October, 2025), Independent Director as Members. Regularize appointment of Mr. Rambhajan Vishwakarma (DIN: 11360922) as Non-Executive, Non-Independent Chairman of the Board. Valuation Update With 7 Day Price Move • Sep 11
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹1.52, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 76% over the past three years. Annuncio • Sep 03
Remedium Lifecare Limited, Annual General Meeting, Sep 24, 2025 Remedium Lifecare Limited, Annual General Meeting, Sep 24, 2025, at 11:00 Indian Standard Time. Reported Earnings • Aug 05
First quarter 2026 earnings released: EPS: ₹0.05 (vs ₹0.04 in 1Q 2025) First quarter 2026 results: EPS: ₹0.05 (up from ₹0.04 in 1Q 2025). Revenue: ₹1.17b (up 50% from 1Q 2025). Net income: ₹46.5m (up 184% from 1Q 2025). Profit margin: 4.0% (up from 2.1% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 1% per year, which means it is well ahead of earnings. Annuncio • Jul 30
Remedium Lifecare Limited to Report Q1, 2026 Results on Aug 04, 2025 Remedium Lifecare Limited announced that they will report Q1, 2026 results on Aug 04, 2025 Valuation Update With 7 Day Price Move • Jul 01
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹1.02, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 19% over the past three years. Valuation Update With 7 Day Price Move • Jun 06
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to ₹1.36, the stock trades at a trailing P/E ratio of 25.8x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 59% over the past three years. Reported Earnings • Jun 02
Full year 2025 earnings released: EPS: ₹0.05 (vs ₹0.81 in FY 2024) Full year 2025 results: EPS: ₹0.05 (down from ₹0.81 in FY 2024). Revenue: ₹4.16b (down 90% from FY 2024). Net income: ₹21.3m (down 94% from FY 2024). Profit margin: 0.5% (down from 0.8% in FY 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 12% per year. Annuncio • May 27
Remedium Lifecare Limited to Report Q4, 2025 Results on May 30, 2025 Remedium Lifecare Limited announced that they will report Q4, 2025 results on May 30, 2025 New Risk • Apr 15
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (₹637.1m market cap, or US$7.43m). New Risk • Mar 18
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₹858.8m (US$9.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Market cap is less than US$10m (₹858.8m market cap, or US$9.92m). Reported Earnings • Feb 16
Third quarter 2025 earnings released: EPS: ₹0.02 (vs ₹1.71 in 3Q 2024) Third quarter 2025 results: EPS: ₹0.02 (down from ₹1.71 in 3Q 2024). Revenue: ₹455.8m (down 98% from 3Q 2024). Net income: ₹7.65m (down 98% from 3Q 2024). Profit margin: 1.7% (down from 2.5% in 3Q 2024). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Feb 08
Remedium Lifecare Limited to Report Q3, 2025 Results on Feb 14, 2025 Remedium Lifecare Limited announced that they will report Q3, 2025 results on Feb 14, 2025 Board Change • Jan 08
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Dipesh Vaidya was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jan 08
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹5.84, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 370% over the past three years. Annuncio • Jan 04
Remedium Lifecare Limited Announces Resignation of Directors Remedium Lifecare Limited informed about the following changes in composition of the Board: (a) Ms. Seema Sanei (DIN: 10549952), has tendered her resignation as an Independent Director of the Company, with effect from closure of business hours on 03 January, 2025, citing pre- occupation and other personal commitments. Consequently, She shall also cease to be a Chairman of the Nomination and Remuneration Committee and Risk Management Committee of the Company. (b) Mr. Pratik Shah (DIN: 06809235), has tendered his resignation as the Independent Director of the Company, with effect from closure of business hours on 03 January, 2025 citing pre- occupation and other personal commitments. Consequently, he shall also cease to be Member of the Stakeholders Relationship, Committee(s) of the Company. Reported Earnings • Nov 16
Second quarter 2025 earnings released: EPS: ₹0.04 (vs ₹0.16 in 2Q 2024) Second quarter 2025 results: EPS: ₹0.04 (down from ₹0.16 in 2Q 2024). Revenue: ₹259.0m (down 95% from 2Q 2024). Net income: ₹17.8m (down 73% from 2Q 2024). Profit margin: 6.9% (up from 1.4% in 2Q 2024). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 74% per year whereas the company’s share price has increased by 75% per year. Annuncio • Nov 09
Remedium Lifecare Limited to Report Q2, 2025 Results on Nov 14, 2024 Remedium Lifecare Limited announced that they will report Q2, 2025 results on Nov 14, 2024 Board Change • Nov 08
High number of new and inexperienced directors There are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Whole Time Director Adarsh Munjal is the most experienced director on the board, commencing their role in 2023. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Nov 05
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹6.44, the stock trades at a trailing P/E ratio of 8.9x. Average trailing P/E is 38x in the Pharmaceuticals industry in India. Total returns to shareholders of 438% over the past three years. Valuation Update With 7 Day Price Move • Oct 16
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹7.53, the stock trades at a trailing P/E ratio of 10.4x. Average trailing P/E is 42x in the Pharmaceuticals industry in India. Total returns to shareholders of 551% over the past three years. Annuncio • Aug 29
Remedium Lifecare to Consider Acquisition of Airowater Global Trading The board of Remedium Lifecare Limited (BSE:539561) will consider acquisition of Airowater Global Trading LLC, UAE, which is into Water Injectables for Pharma Production. Reported Earnings • Aug 15
First quarter 2025 earnings released: EPS: ₹0.16 (vs ₹0.15 in 1Q 2024) First quarter 2025 results: EPS: ₹0.16. Revenue: ₹795.9m (down 80% from 1Q 2024). Net income: ₹16.4m (down 72% from 1Q 2024). Profit margin: 2.1% (up from 1.5% in 1Q 2024). The increase in margin was driven by lower expenses. Annuncio • Aug 14
Remedium Lifecare Limited Appoints Neeraj Ramashankar Yadav as Whole Time Company Secretary and Compliance Officer Remedium Lifecare Limited announced that the company has appointed Mr. Neeraj Ramashankar Yadav as whole time company secretary and compliance officer of the company pursuant to the provisions of section 203 of Companies Act, 2013 and Compliance Officer under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Date of appointment is August 14, 2024. Mr. Neeraj Ramashankar Yadav is an Associate member of Institute of Company Secretaries of India, a Commerce Graduate and a Law Graduate (L.L.B) from University of Mumbai and having Overall experience in the field of Companies Act, SEBI Regulations, and Corporate legal Matters. He is not related to any directors of the company. Valuation Update With 7 Day Price Move • Aug 14
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₹9.75, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 740% over the past three years. Valuation Update With 7 Day Price Move • Jul 25
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₹15.00, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 36x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,184% over the past three years. Annuncio • Jul 16
Remedium Lifecare Limited to Report Q1, 2025 Results on Aug 08, 2024 Remedium Lifecare Limited announced that they will report Q1, 2025 results on Aug 08, 2024 Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹78.30, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total returns to shareholders of 2,034% over the past three years. Annuncio • Jun 15
Remedium Lifecare Limited Announces the Resignation of Dhwani Desai as Company Secretary and Compliance Officer Remedium Lifecare Limited announced that Ms. Dhwani Desai, Company Secretary and Compliance Officer, Key Managerial Personnel (KMP) of the Company, vide her letter dated June 14, 2024, has tendered her resignation from the services of the Company, due to personal reasons. She shall be relieved of her duties with effect from the close of business hours of June 14, 2024. Annuncio • Jun 05
Remedium Lifecare Limited, Annual General Meeting, Jun 26, 2024 Remedium Lifecare Limited, Annual General Meeting, Jun 26, 2024, at 11:00 Indian Standard Time. Reported Earnings • May 28
Full year 2024 earnings released: EPS: ₹90.92 (vs ₹0.54 in FY 2023) Full year 2024 results: EPS: ₹90.92 (up from ₹0.54 in FY 2023). Revenue: ₹40.6b (up ₹35.5b from FY 2023). Net income: ₹327.3m (up ₹273.0m from FY 2023). Profit margin: 0.8% (down from 1.1% in FY 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 154% per year but the company’s share price has increased by 179% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 10
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹84.10, the stock trades at a trailing P/E ratio of 16.1x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 2,988% over the past three years. Annuncio • May 05
Remedium Lifecare Limited to Report Q4, 2024 Results on May 10, 2024 Remedium Lifecare Limited announced that they will report Q4, 2024 results on May 10, 2024 Board Change • Apr 20
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Trupti Bolke was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to ₹98.50, the stock trades at a trailing P/E ratio of 18.8x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 6,063% over the past three years. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 43% After last week's 43% share price gain to ₹670, the stock trades at a trailing P/E ratio of 25.6x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 7,858% over the past three years. Reported Earnings • Feb 15
Third quarter 2024 earnings released: EPS: ₹34.12 (vs ₹0.76 in 3Q 2023) Third quarter 2024 results: EPS: ₹34.12 (up from ₹0.76 in 3Q 2023). Revenue: ₹18.5b (up ₹16.7b from 3Q 2023). Net income: ₹687.8m (up ₹672.6m from 3Q 2023). Profit margin: 3.7% (up from 0.9% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has increased by 317% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Feb 07
Remedium Lifecare Limited to Report Nine Months, 2024 Results on Feb 14, 2024 Remedium Lifecare Limited announced that they will report nine months, 2024 results on Feb 14, 2024 New Risk • Dec 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (55% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (7.2% average weekly change). Profit margins are more than 30% lower than last year (0.8% net profit margin). Annuncio • Nov 22
Remedium Lifecare Limited Appoints Dhwani Desai as Whole Time Company Secretary and Compliance Officer Remedium Lifecare Limited announced that the company has appointed Mrs. Dhwani Desai as Whole time Company Secretary and Compliance officer of the Company. Mrs. Dhwani Desai is Member of Institute of Company Secretaries of India and having ASC No. A63688 and requisite qualification to hold position of the whole time Company Secretary and Compliance Officer of the Company. Mrs. Dhwani Desai will be responsible for all functions of Company Secretary as prescribed under Section 205 of Companies Act, 2013. She will also be the Compliance officer as required under Regulation 6 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. She has experience of 3 years dealing with Secretarial Compliances. Date of Appointment is November 20, 2023. New Risk • Nov 19
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 0.8% Last year net profit margin: 1.6% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (55% accrual ratio). Minor Risk Profit margins are more than 30% lower than last year (0.8% net profit margin). Annuncio • Sep 09
Remedium Lifecare Limited Announces Resignation of Ashvini Dhuri as Company Secretary / Compliance Officer Remedium Lifecare Limited informed that Ms. Ashvini Dhuri (Membership No. A66051), Company Secretary and Compliance Officer, Key Managerial Personnel (KMP) of the Company, vide her letter dated 8th September 2023, has submitted her resignation from the services of the Company. She shall be relieved of her duties with effect from the close of business hours on Friday, September 08, 2023. The Company places on record the valuable contribution and guidance provided by Ms. Ashvini Dhuri, during her tenure as Company Secretary and Compliance Officer of the Company. The Company is in the process of appointing a successor for the position of Company Secretary and Compliance Officer, which shall be duly intimated to the Stock Exchange in due course. Annuncio • Aug 27
Remedium Lifecare Limited Announces the Resignation of Dr. Vilas Ramkrishna Lokhande from the Position of Whole Time Director Remedium Lifecare Limited announced the resignation of Dr. Vilas Ramkrishna Lokhande (DIN: 01228041) from the position of Whole Time Director of the Company. Annuncio • Aug 04
Remedium Lifecare Limited to Report Q1, 2024 Results on Aug 12, 2023 Remedium Lifecare Limited announced that they will report Q1, 2024 results on Aug 12, 2023 New Risk • Jul 27
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹5.39b (US$65.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.1% average weekly change). Market cap is less than US$100m (₹5.39b market cap, or US$65.5m). Annuncio • Jun 24
Remedium Lifecare Limited, Annual General Meeting, Jul 20, 2023 Remedium Lifecare Limited, Annual General Meeting, Jul 20, 2023, at 11:00 Indian Standard Time. New Risk • Jun 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Jun 02
Full year 2023 earnings released: EPS: ₹15.07 (vs ₹2.99 in FY 2022) Full year 2023 results: EPS: ₹15.07 (up from ₹2.99 in FY 2022). Revenue: ₹5.10b (up 1.0% from FY 2022). Net income: ₹54.3m (up 403% from FY 2022). Profit margin: 1.1% (up from 0.2% in FY 2022). Annuncio • May 25
Remedium Lifecare Limited to Report Q4, 2023 Results on May 30, 2023 Remedium Lifecare Limited announced that they will report Q4, 2023 results on May 30, 2023 Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹1,090, the stock trades at a trailing P/E ratio of 43.4x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total returns to shareholders of 4,786% over the past three years. Valuation Update With 7 Day Price Move • Mar 02
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₹298, the stock trades at a trailing P/E ratio of 11.9x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 1,373% over the past three years. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹216, the stock trades at a trailing P/E ratio of 8.6x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total returns to shareholders of 969% over the past three years. Reported Earnings • Feb 09
Third quarter 2023 earnings released Third quarter 2023 results: EPS: ₹4.23. Revenue: ₹1.77b (down 14% from 3Q 2022). Net income: ₹15.2m (up 122% from 3Q 2022). Profit margin: 0.9% (up from 0.3% in 3Q 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 84% per year but the company’s share price has increased by 133% per year, which means it is tracking significantly ahead of earnings growth. Annuncio • Jan 31
Remedium Lifecare Limited to Report Q3, 2023 Results on Feb 07, 2023 Remedium Lifecare Limited announced that they will report Q3, 2023 results on Feb 07, 2023 Valuation Update With 7 Day Price Move • Jan 19
Investor sentiment improved over the past week After last week's 20% share price gain to ₹169, the stock trades at a trailing P/E ratio of 7.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 697% over the past three years. Annuncio • Nov 16
Remedium Lifecare Limited (BSE : 539561) entered into an Memorandum of Understanding to acquire Mvk Lifesciences Private Limited. Remedium Lifecare Limited (BSE : 539561) entered into an Memorandum of Understanding to acquire Mvk Lifesciences Private Limited on November 14, 2022. Remedium Lifecare Limited board approved the merger. Reported Earnings • Nov 06
Second quarter 2023 earnings released: EPS: ₹6.08 (vs ₹3.06 in 2Q 2022) Second quarter 2023 results: EPS: ₹6.08 (up from ₹3.06 in 2Q 2022). Revenue: ₹1.60b (up 33% from 2Q 2022). Net income: ₹21.9m (up 99% from 2Q 2022). Profit margin: 1.4% (up from 0.9% in 2Q 2022). The increase in margin was driven by higher revenue. Annuncio • Oct 19
Remedium Lifecare Limited to Report Q2, 2023 Results on Nov 04, 2022 Remedium Lifecare Limited announced that they will report Q2, 2023 results on Nov 04, 2022 Annuncio • Aug 27
Remedium Lifecare Limited, Annual General Meeting, Sep 20, 2022 Remedium Lifecare Limited, Annual General Meeting, Sep 20, 2022, at 10:00 Indian Standard Time. Reported Earnings • Aug 18
First quarter 2023 earnings released First quarter 2023 results: EPS: ₹18.04. Revenue: ₹993.3m (down 28% from 1Q 2022). Net income: ₹65.0m (up ₹60.4m from 1Q 2022). Profit margin: 6.5% (up from 0.3% in 1Q 2022). The increase in margin was driven by lower expenses. Reported Earnings • Jun 04
Full year 2022 earnings released Full year 2022 results: Revenue: ₹5.05b (up 461% from FY 2021). Net income: ₹10.8m (up 124% from FY 2021). Profit margin: 0.2% (down from 0.5% in FY 2021). The decrease in margin was driven by higher expenses. Annuncio • May 25
Remedium Lifecare Limited to Report Q4, 2022 Results on May 30, 2022 Remedium Lifecare Limited announced that they will report Q4, 2022 results on May 30, 2022 Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Trupti Bolke was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 11
Third quarter 2022 earnings: Revenues in line with analyst expectations Third quarter 2022 results: Revenue: ₹2.06b (up 495% from 3Q 2021). Net income: ₹6.87m (up 229% from 3Q 2021). Profit margin: 0.3% (down from 0.6% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Annuncio • Feb 03
Remedium Lifecare Limited to Report Q3, 2022 Results on Feb 09, 2022 Remedium Lifecare Limited announced that they will report Q3, 2022 results on Feb 09, 2022 Board Change • Sep 15
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Woman Director Maneesha Naresh is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 13
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Woman Director Maneesha Naresh is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 11
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Woman Director Maneesha Naresh is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 09
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. No highly experienced directors. Independent Woman Director Maneesha Naresh is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Jul 20
Woman Independent Director recently bought ₹487k worth of stock On the 16th of July, Maneesha Naresh bought around 4k shares on-market at roughly ₹127 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought ₹1.7m more in shares than they have sold in the last 12 months. Executive Departure • Jul 15
Company Secretary & Compliance Officer Nishant Phadtare has left the company On the 7th of July, Nishant Phadtare's tenure as Company Secretary & Compliance Officer ended after 1.9 years in the role. We don't have any record of a personal shareholding under Nishant's name. Nishant is the only executive to leave the company over the last 12 months. Reported Earnings • Jul 08
First quarter 2022 earnings released The company reported a solid first quarter result with improved earnings and revenues, although profit margins were weaker. First quarter 2022 results: Revenue: ₹1.38b (up ₹1.38b from 1Q 2021). Net income: ₹4.52m (up ₹4.37m from 1Q 2021). Profit margin: 0.3% (down from 6.7% in 1Q 2021). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • May 05
Investor sentiment improved over the past week After last week's 15% share price gain to ₹57.65, the stock trades at a trailing P/E ratio of 74.9x. Average trailing P/E is 24x in the Machinery industry in India. Annuncio • Feb 04
Remedium Lifecare Limited to Report Q3, 2020 Results on Feb 12, 2021 Remedium Lifecare Limited announced that they will report Q3, 2020 results on Feb 12, 2021 Valuation Update With 7 Day Price Move • Feb 01
Investor sentiment deteriorated over the past week After last week's 17% share price decline to ₹48.90, the stock is trading at a trailing P/E ratio of 63.5x, down from the previous P/E ratio of 76.6x. This compares to an average P/E of 21x in the Machinery industry in India. Total returns to shareholders over the past year are 141%. Valuation Update With 7 Day Price Move • Jan 15
Investor sentiment improved over the past week After last week's 15% share price gain to ₹57.70, the stock is trading at a trailing P/E ratio of 74.9x, up from the previous P/E ratio of 64.9x. This compares to an average P/E of 26x in the Machinery industry in India. Total returns to shareholders over the past year are 172%. Is New 90 Day High Low • Jan 07
New 90-day high: ₹50.00 The company is up 64% from its price of ₹30.40 on 09 October 2020. The Indian market is up 20% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 26% over the same period. Valuation Update With 7 Day Price Move • Dec 31
Investor sentiment improved over the past week After last week's 18% share price gain to ₹47.25, the stock is trading at a trailing P/E ratio of 61.4x, up from the previous P/E ratio of 52.2x. This compares to an average P/E of 24x in the Machinery industry in India. Total returns to shareholders over the past year are 112%. Is New 90 Day High Low • Dec 16
New 90-day high: ₹32.80 The company is up 6.0% from its price of ₹30.95 on 17 September 2020. The Indian market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period. Valuation Update With 7 Day Price Move • Dec 16
Investor sentiment improved over the past week After last week's 20% share price gain to ₹32.80, the stock is trading at a trailing P/E ratio of 42.6x, up from the previous P/E ratio of 35.5x. This compares to an average P/E of 24x in the Machinery industry in India. Is New 90 Day High Low • Nov 19
New 90-day low: ₹29.45 The company is down 27% from its price of ₹40.20 on 21 August 2020. The Indian market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 9.0% over the same period. Annuncio • Nov 08
Remedium Lifecare Limited to Report Q2, 2021 Results on Nov 13, 2020 Remedium Lifecare Limited announced that they will report Q2, 2021 results on Nov 13, 2020 Annuncio • Oct 01
Roxy Exports Limited Approves Appointment of Ms. Trupti Bolke as an Independent Director Roxy Exports Limited at AGM held on September 30, 2020 approved the appointment of Ms. Trupti Bolke (DIN: 07700551) as an Independent Director of the Company. Annuncio • Jun 20
Roxy Exports Limited to Report Q4, 2020 Results on Jun 27, 2020 Roxy Exports Limited announced that they will report Q4, 2020 results on Jun 27, 2020 
